title: Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
abstract: BACKGROUND
  To evaluate the feasibility and security of complete remission (CR) of advanced hepatocellular carcinoma (HCC) achieved with sorafenib treatment, and investigate the previously described predictive factors in CR.
  
  
  METHODS
  The case of a patient who achieved CR of advanced HCC with sorafenib treatment was analyzed. The case analysis was performed by a literature review of relevant reports retrieved from the PubMed database.
  
  
  RESULTS
  A 58-year-old male patient achieved CR of advanced HCC after 23 weeks of oral treatment with sorafenib alone for 41 months and maintained CR for more than 35 months. Eleven reports worldwide have documented a total of twelve patients who achieved CR of advanced HCC, including six with nonsurgical oral sorafenib treatment, four with surgical resection in the descent stage following oral sorafenib treatment and two with oral sorafenib treatment for postoperative metastasis.
  
  
  CONCLUSIONS
  For unresectable advanced HCC, sorafenib can significantly improve progression-free survival and overall survival, achieving CR in some cases. In addition, surgical resection of advanced HCC in the descent stage is possible following oral sorafenib treatment. For patients with postoperative distant metastasis of HCC, sorafenib treatment also provides clinical benefits and can even achieve CR. Besides, long-term sorafenib administration is safe, and patients should continually receive sorafenib to avoid recurrence after complete remission of cancer. Furthermore, early HFSR, rapid decline of AFP levels and rapid tumor shrinking observed by imaging are known parameters describing sorafenib's effects. Finally, it is important to assess the gene locus of sorafenib sensitivity in HCC patients in future research.
authors: Department of Surgery, Sichuan Cancer Hospital, Chengdu, 610041, Sichuan Province, China. liudaizhongcd@163.com.
authors: Daizhong
authors: D
authors: Liu
authors: Department of Surgery, Sichuan Cancer Hospital, Chengdu, 610041, Sichuan Province, China. liuaixiangcd@163.com.
authors: Aixiang
authors: A
authors: Liu
authors: Department of Surgery, Sichuan Cancer Hospital, Chengdu, 610041, Sichuan Province, China. schpjp@163.com.
authors: Junping
authors: J
authors: Peng
authors: Department of Surgery, Sichuan Cancer Hospital, Chengdu, 610041, Sichuan Province, China. hu1999hyq@126.com.
authors: Yong
authors: Y
authors: Hu
authors: Department of Surgery, Sichuan Cancer Hospital, Chengdu, 610041, Sichuan Province, China. Llxxff17@163.com.
authors: Xielin
authors: X
authors: Feng
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000188:drug therapy*; D018572:Disease-Free Survival; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
references: Oncology. 2011;81 Suppl 1:152-7
references: 22212950
references: Am J Transplant. 2009 Dec;9(12):2851-4
references: 20021481
references: Oncologist. 2010;15(1):85-92
references: 20051477
references: Am J Gastroenterol. 2009 Jul;104(7):1852-4
references: 19574982
references: Med Oncol. 2011 Dec;28 Suppl 1:S165-8
references: 20809183
references: Target Oncol. 2010 Mar;5(1):59-63
references: 20309643
references: J Gastrointest Cancer. 2013 Mar;44(1):98-101
references: 23054578
references: N Engl J Med. 2008 Jul 24;359(4):378-90
references: 18650514
references: Liver Int. 2011 May;31(5):740-3
references: 21457447
references: Onkologie. 2007 Oct;30(10):519-24
references: 17890892
references: Cancer. 2010 Oct 1;116(19):4590-6
references: 20572033
references: Case Rep Oncol. 2012 May;5(2):380-4
references: 23525021
references: Oncogene. 2006 Oct 5;25(45):6056-66
references: 16652141
references: Lancet Oncol. 2009 Jan;10(1):25-34
references: 19095497
references: World J Gastrointest Oncol. 2013 Feb 15;5(2):38-42
references: 23556056
references: J Hematol Oncol. 2008;1:18
references: 18928548
references: Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):353-67
references: 19673623
references: BMC Gastroenterol. 2011;11:4
references: 21241463
references: J Clin Oncol. 2011 Apr 20;29(12):e330-2
references: 21263091
references: Cancer Res. 2006 Dec 15;66(24):11851-8
references: 17178882
references: J Hepatol. 2001 Apr;34(4):570-5
references: 11394657